For the year ending 2025-12-31, CTKB had -$7,892K decrease in cash & cash equivalents over the period. -$8,770K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -66,539 |
| Depreciation and amortization | 7,579 |
| Amortization of operating lease-right-of use assets | 4,396 |
| Provision for (benefit from) credit losses | 413 |
| Stock-based compensation | 24,585 |
| Loss on disposal of property and equipment | -415 |
| Provision for excess and obsolete inventory | 1,703 |
| Deferred income taxes | 33,557 |
| Gain on investments, accretion, and amortization, net | -5,673 |
| Interest expenses for accretion of the legal settlement liabilities | -328 |
| Trade accounts receivable | -368 |
| Inventories | 5,244 |
| Prepaid expenses and other assets | 2,658 |
| Trade accounts payable | 448 |
| Accrued expenses and other liabilities | 3,970 |
| Legal settlement liabilities | -1,133 |
| Deferred revenue | 3,601 |
| Lease liabilities | 4,146 |
| Net cash provided by (used in) operating activities | -4,686 |
| Purchases of marketable securities | -278,155 |
| Maturities of marketable securities | 292,211 |
| Purchase of property and equipment | 4,084 |
| Proceeds from sales of property and equipment | 252 |
| Acquisition of business | 0 |
| Purchase of intangible assets (patents) | 106 |
| Payment for additional investment in cytek japan, net of cash acquired | 0 |
| Net cash provided by (used in) investing activities | 10,117 |
| Proceeds from line of credit | 5,582 |
| Payment for repurchase of shares | 15,074 |
| Repayment of loan | 4,745 |
| Proceeds from employee stock purchase plan | 1,149 |
| Payments for taxes related to net share settlement of equity awards | 670 |
| Proceeds from issuance of common stock under employee stock plans | 325 |
| Net cash used in financing activities | -13,432 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 109 |
| Net decrease in cash, cash equivalents and restricted cash | -7,892 |
| Cash, cash equivalents and restricted cash at beginning of period | 98,745 |
| Cash, cash equivalents and restricted cash at end of period | 90,853 |
Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB)